Reply to the Letter to the Editor "Odronextamab against relapsed or refractory follicular lymphoma" by Y. Shimazu

Ann Oncol. 2024 Oct 21:S0923-7534(24)04065-1. doi: 10.1016/j.annonc.2024.10.016. Online ahead of print.

Authors

T M Kim¹, A Chaudhry², H Mohamed², B Shen², S Ambati²

Affiliations

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: gabriel9@snu.ac.kr.
² Regeneron Pharmaceuticals, Inc., Tarrytown, USA.

PMID: 39442616
DOI: 10.1016/j.annonc.2024.10.016

No abstract available

Publication types

Letter